K. Azuma
Impact in
-
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
-
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
Papers in
-
- Lung Cancer Treatments and Mutations 5
- Lung Cancer Diagnosis and Treatment 1
-
- Myasthenia Gravis and Thymoma 2
- Neuroblastoma Research and Treatments 1
- Co-authors
- Shiro Akinaga (1 shared paper)K. Park (1 shared paper)Tetsuya Mitsudomi (1 shared paper)Makoto Maemondo (2 shared papers)Nobuyuki Katakami (1 shared paper)C.-M. Tsai (1 shared paper)Kazuhiko Nakagawa (1 shared paper)Nobuyuki Yamamoto (1 shared paper)
- Journals
- Annals of Oncology (4 papers)Japanese Journal of Clinical Oncology (2 papers)Cancers (1 paper)The Oncologist (1 paper)BMC Research Notes (1 paper)
- Partner nations
- JapanUnited StatesTaiwan
In The Last Decade
K. Azuma
9 papers receiving 495 citations
K. Azuma's Hit Papers
Peers
Comparison fields: 5 of 45
- Pulmonary and Respiratory Medicine 329
- Oncology 157
- Hepatology 43
- Cancer Research 43
- Pathology and Forensic Medicine 38
Countries citing papers authored by K. Azuma
This map shows the geographic impact of K. Azuma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Azuma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Azuma more than expected).
Fields of papers citing papers by K. Azuma
This network shows the impact of papers produced by K. Azuma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Azuma. The network helps show where K. Azuma may publish in the future.
Co-authors
The 25 scholars most cited alongside K. Azuma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study Hit paper breakdown → | 2023 | 292 |
| 2 | 2015 | 101 | |
| 3 | Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA Hit paper breakdown → | 2024 | 64 |
| 4 | 2018 | 22 | |
| 5 | 2011 | 12 | |
| 6 | 2015 | 7 | |
| 7 | 2014 | 3 | |
| 8 | 2022 | 2 | |
| 9 | 2018 | 1 |
About K. Azuma
K. Azuma is a scholar working on Pulmonary and Respiratory Medicine, Neurology, Endocrinology, Diabetes and Metabolism, Radiology, Nuclear Medicine and Imaging and Oncology, having authored 9 papers that have together received 504 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (5 papers), Myasthenia Gravis and Thymoma (2 papers), Radiomics and Machine Learning in Medical Imaging (1 paper), Lung Cancer Diagnosis and Treatment (1 paper), Lung Cancer Research Studies (1 paper), Neutropenia and Cancer Infections (1 paper), Neuroblastoma Research and Treatments (1 paper) and Pituitary Gland Disorders and Treatments (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (329 citations), Oncology (157 citations), Hepatology (43 citations), Cancer Research (43 citations) and Pathology and Forensic Medicine (38 citations). K. Azuma has collaborated with scholars based in Japan, United States and Taiwan. Frequent co-authors include Shiro Akinaga, K. Park, Tetsuya Mitsudomi, Makoto Maemondo, Nobuyuki Katakami, C.-M. Tsai, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Myung‐Ju Ahn and Toshiaki Takahashi. Their work appears in journals such as Annals of Oncology, Japanese Journal of Clinical Oncology, Cancers, The Oncologist and BMC Research Notes.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.